nach oben

Erschienen in:

16.07.2019 | Clinical trial

The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry

verfasst von: Sang eun Nam, Woosung Lim, Joon Jeong, Seeyoun Lee, Jungeun Choi, HeungKyu Park, Yong Sik Jung, Seung Pil Jung, Soo Youn Bae

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) are widely used for monitoring breast cancer. However, the prognostic efficacy of preoperative elevations of CEA and CA15-3 levels in breast cancer patients remains controversial.

Methods

We retrospectively analyzed the clinicopathological parameters of 149,238 patients in the Korean Breast Cancer Society Registry Database who underwent surgery between January 2000 and December 2015.

Results

The patients with elevated CA15-3/CEA levels had worse overall survival (OS) than the patients with normal CA15-3/CEA levels. For the luminal A subtype, the CA15-3- and CEA-elevated group had a hazard ratio (HR) of 2.14 (95% CI 1.01–4.55). The CA15-3-elevated group had an HR of 2.38 (95% CI 1.58–3.58) and the CEA-elevated group had an HR of 1.79 (95% CI 1.20–2.68) compared to the normal group. For the luminal B subtype, the CA15-3- and CEA-elevated group had an HR of 3.99 (95% CI 2.23–7.16), whereas the CA15-3-elevated group had an HR of 2.38 (95% CI 1.58–3.58) and the CEA-elevated group had an HR of 1.79 (95% CI 1.20–2.68). For the HER2 subtype, elevated CEA level was the only independent prognostic factor. However, for the triple-negative breast cancer (TNBC) subtype, elevated preoperative CEA and CA15-3 levels were not significant prognostic factors for OS.

Conclusion

Preoperative CEA and CA15-3 levels showed varying prognostic ability according to breast cancer subtype. Preoperative CA15-3 and CEA elevation are significant prognostic factors for luminal breast cancer, but they were not significant factors for TNBC.

Park EH, Min SY, Kim Z, Yoon CS, Jung KW, Nam SJ, Oh SJ, Lee S, Park BW, Lim W, Hur MH (2017) Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer 20(1):1–11CrossRefPubMedPubMedCentral

Schnitt SJ (2010) Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathol Suppl 2:S60–S64CrossRef

Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 21:439–462CrossRef

Hammarström S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9(2):67–81CrossRefPubMed

Kabel AM (2017) Tumor markers of breast cancer: new prospectives. J Oncol Sci 3(1):5–11

Duffy MJ, Evoy D, McDermott EW (2010) CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 411(23):1869–1874CrossRefPubMed

O’Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF (1995) An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 71(6):1288–1291CrossRefPubMedPubMedCentral

Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T (2008) Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 13(5):447–451CrossRefPubMed

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312CrossRef

10.

NCCN. NCCN guidelines Version 4. 2018 Breast cancer 2018 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf]

11.

Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M et al (2005) Tumor markers in breast cancer- european group on tumor markers recommendations. Tumour Biol 26(6):281–293CrossRefPubMed

12.

Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH et al (2008) Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19(4):675–681CrossRefPubMed

13.

Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW (2013) Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 24(5):1225–1231CrossRefPubMed

14.

Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM et al (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: american society of clinical oncology clinical practice guidelines. J Clin Oncol 33(24):2695–2704CrossRefPubMedPubMedCentral

15.

Shao Y, Sun X, He Y, Liu C, Liu H (2015) Elevated levels of serum tumor markers CEA and CA 15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE 10(7):e0133830CrossRefPubMedPubMedCentral

16.

Wu S-g, He Z-y, Zhou J, Sun J-y, Li F-y, Lin Q et al (2014) Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast 23(1):88–93CrossRefPubMed

17.

Manuali E, De Giuseppe A, Feliziani F, Forti K, Casciari C, Marchesi MC et al (2012) CA 15–3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res 8(1):86CrossRefPubMedPubMedCentral

18.

Martin A, Corte MD, Álvarez AM, Rodriguez JC, Andicoechea A, Bongera M et al (2006) Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res 26(5):3965–3971PubMed

19.

Agrawal AK, Jelen M, Rudnicki J, Grzebieniak Z, Zysko D, Kielan W et al (2010) The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. Folia Histochem Cytobiol 48(1):26–29CrossRefPubMed

20.

Li X, Dai D, Chen B, Tang H, Xie X, Wei W (2018) Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Mark 2018:9863092

21.

Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B et al (2012) Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 23(2):338–345CrossRefPubMed

22.

Li H, Chen K, Su F, Song E, Gong C (2014) Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. J Surg Res 189(1):48–56CrossRefPubMed

23.

Molina R, Auge JM, Escudero JM, Filella X, Zanon G, Pahisa J et al (2010) Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 31(3):171–180CrossRefPubMed

24.

Dai D, Chen B, Tang H, Wang B, Zhao Z, Xie X et al (2016) Nomograms for predicting the prognostic value of pre-therapeutic CA15-3 and CEA serum levels in TNBC patients. PLoS ONE 11(8):e0161902CrossRefPubMedPubMedCentral

25.

Charbonneau J, Stanners CP (1999) Role of carbohydrate structures in CEA-mediated intercellular adhesion. Cell Adhes Commun 7(3):233–244CrossRefPubMed

26.

Klaile E, Klassert TE, Scheffrahn I, Muller MM, Heinrich A, Heyl KA et al (2013) Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respir Res 14:85CrossRefPubMedPubMedCentral

27.

Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD et al (2005) Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 174(11):6692–6701CrossRefPubMed

28.

Sulekha Dhanisha S, Guruayoorappan C, Drishya S, Prathapan A (2017) Mucins: structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit Rev Oncol/Hematol 122:98–122CrossRef

29.

Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J (1984) Differential reactivity of a novel monoclonal antibody (df3) with human malignant versus benign breast tumors. Hybridoma 3(3):223–232CrossRefPubMed

30.

Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW (1985) Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Investig 75(5):1671–1678CrossRefPubMed

31.

Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4:45CrossRefPubMed

32.

Wei X, Xu H, Kufe D (2006) MUC1 oncoprotein stabilizes and activates estrogen receptor α. Mol Cell 21(2):295–305CrossRefPubMed

33.

Singh PK, Hollingsworth MA (2006) Cell surface-associated mucins in signal transduction. Trends Cell Biol 16(9):467–476CrossRefPubMed

34.

Haddon L, Hugh J (2015) MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad. Clin Exp Metas 32(4):393–403CrossRef

35.

Merikhian P, Ghadirian R, Farahmand L, Mansouri S, Majidzadeh AK (2017) MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther 17(7):607–613CrossRefPubMed

Titel: The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry
verfasst von: Sang eun Nam
Woosung Lim
Joon Jeong
Seeyoun Lee
Jungeun Choi
HeungKyu Park
Yong Sik Jung
Seung Pil Jung
Soo Youn Bae
Publikationsdatum: 16.07.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05357-y

Springer Medizin

The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry